Aripiprazole/sertraline
Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), and aripiprazole (Abilify), an atypical antipsychotic, which is under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] The drug combines serotonin reuptake inhibition and modulation of dopamine and serotonin receptors.[1] As of July 2017, it is in preregistration in Japan for the treatment of MDD.[1]
| Combination of | |
|---|---|
| Sertraline | Selective serotonin reuptake inhibitor |
| Aripiprazole | Atypical antipsychotic |
| Clinical data | |
| Other names | ASC-01 |
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
External links
| D1-like |
| ||||
|---|---|---|---|---|---|
| D2-like |
| ||||
| |||||
| DAT (DRIs) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NET (NRIs) |
| ||||||||||||||
| SERT (SRIs) |
| ||||||||||||||
| VMATs |
| ||||||||||||||
| Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins | |||||||||||||||
Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.